Free scoping read. A written assessment of your manuscript in two business days, at no cost.

Start one
Contents

Academy · Research Data, Analytics & AI · Medical Supply Chain Review

Mapping the Pandemic-Era Medical Supply Chain Literature: A Structured Review

A structured scoping review of 47 studies on the pharmaceutical supply chain during COVID-19 found disruption driven by three forces: constrained production and border closures, surging healthcare demand, and shifting consumer purchasing behaviour.

Pubrica AcademyWritten by a health systems research analyst Reviewed bya supply chain research methodologist Published10 October 2026 Last checked10 October 2026 Reading time6 minutes Sources10 peer-reviewed

Reviewing the pandemic-era medical supply chain literature means systematically mapping what researchers found when production, demand and distribution for pharmaceuticals and health products were disrupted simultaneously by COVID-19. Ferdous, Medhekar, Akbar, Khandaker and Hossain, publishing in the Australasian Journal of Regional Studies, conducted a scoping review following PRISMA guidelines, screening down to 47 full-text articles to build an analytical framework for depicting pharmaceutical supply chain disruption during the pandemic.

Learning objectives

  • A PRISMA-guided scoping review is a structured method for mapping a fast-growing, cross-disciplinary literature such as pandemic supply chain research.
  • The reviewed literature identifies three primary drivers of pharmaceutical supply chain disruption during COVID-19: reduced product supply, higher healthcare demand, and shifting purchasing behaviour.
  • Reduced product supply during the pandemic was driven by production halts and border closures rather than a single bottleneck.
  • The resulting analytical framework was built specifically to support further research into regional pharmaceutical supply chain disruption, in Australia and internationally.

Common misconceptions

  • “Pandemic-era medical supply shortages were mainly a demand-side problem — people simply bought more than usual.” The scoping review by Ferdous et al. identifies reduced product supply, caused by production halts and border closures, as a distinct and co-equal driver of disruption alongside higher demand and changed purchasing behaviour, not merely a consequence of demand spikes.
  • “Pharmaceutical supply chain disruption during COVID-19 was a uniform, global phenomenon best studied at the global level.” The review's resulting framework was explicitly built to map disruption at a regional level, in Australian and comparable settings, because the production, border and demand effects identified play out differently across regions rather than as a single global pattern.

Review methodology

Ferdous, Medhekar, Akbar, Khandaker and Hossain conducted a scoping review following PRISMA guidelines, screening the pandemic-era supply chain literature down to 47 full-text articles for detailed analysis1. A PRISMA-guided scoping approach, rather than a narrower systematic review, suited the subject because pandemic supply chain research accumulated rapidly across health, logistics and policy journals, and a scoping method is built to map the breadth of a fast-growing literature rather than answer a single narrow empirical question.

Three drivers of pharmaceutical supply chain disruption

Across the 47 studies, the review identified three recurring drivers of disruption to the pharmaceutical supply chain (PSC) during COVID-19: lower product supply caused by production halts and border closures, higher demand for healthcare products, and shifts in consumer purchasing behaviour1. The review’s framing treats these as distinct, co-occurring mechanisms rather than a single shock, a distinction that matters for how a health system or supplier plans a response, since a production-side disruption requires a different mitigation from a demand-side surge.

The resulting analytical framework

The review's stated purpose was to build an analytical framework for depicting pharmaceutical supply chain disruption, intended to support further research into regional supply chain resilience in Australia and comparable settings1. A structured review that produces a reusable framework, rather than only a narrative summary, gives subsequent researchers a common set of categories — supply-side, demand-side and behavioural drivers — against which new regional or product-specific disruption data can be mapped and compared.

Growth of the pandemic supply chain literature

Two independent bibliometric analyses document how rapidly this literature expanded, which supports the choice of a scoping method rather than a narrow systematic review. Sovero Castro, Risco Guevara and Garcia Lopez identified 785 publications on the pharmaceutical supply chain between 2010 and 2021 across Scopus and Web of Science, concentrated in institutions in Iran, Morocco and Saudi Arabia, and noted that even by 2021 relatively few of those publications were specifically about COVID-192. A separate, more recent analysis by Dienes, Qorri and Felföldi, focused specifically on pharmaceutical supply chain resilience, found 41 Scopus-indexed documents published between 2012 and 2024, with none between 2013 and 2015, and a sharp rise after 2020 that the authors attribute largely to COVID-19, with research themes clustering around risk mitigation, stakeholder collaboration, and technology-driven resilience tools such as the Internet of Things (IoT) and blockchain2. Taken together, these two bibliometric studies indicate that the pandemic did not merely add a small number of papers to an existing literature but reshaped a previously limited research area around a new set of resilience-focused themes.

Worked example: the global shortage of personal protective equipment

The “reduced product supply” driver of the Ferdous et al. framework is most clearly illustrated by the global shortage of personal protective equipment (PPE) that characterized the pandemic’s early months. The Asian Development Bank’s analysis of PPE supply chains, covering protective suits, surgical masks, gowns and gloves, traced the shortage to production bottlenecks concentrated in a small number of manufacturing hubs, compounded by export restrictions as individual governments moved to secure domestic supply first3. Its recommended remedy was not a single-country solution but international cooperation to expand production capacity and improve resource allocation across borders, which is consistent with the broader point in the pharmaceutical supply chain literature that a supply-side shock concentrated in a few producing regions requires a coordinated, multi-country response rather than an attempt by one country to out-produce the shortage alone3.

Worked example: India’s export restrictions on active pharmaceutical ingredients

The same supply-side driver is even more pronounced in active pharmaceutical ingredients (APIs). In March 2020, India restricted export of 26 APIs — roughly 10% of its export capacity — covering products including paracetamol, several antibiotics, progesterone and vitamin B12, in order to protect its own domestic market first4. The restriction had global consequences because India supplies around 20% of the world’s generic medicines and roughly a quarter of all US drug imports, while Indian manufacturers themselves depend on China for an estimated 66-70% of their own active ingredients, meaning that the same disruption propagated through at least two tiers of an already concentrated global supply chain before reaching patients4. This double dependency illustrates why the Ferdous et al. framework treats “reduced product supply” as a distinct category meriting separate analysis: a shortage of a specific drug can originate two or three supply tiers away from where its effects are ultimately experienced.

Distinct disruption pattern in vaccine supply

Not every part of the pandemic-era medical supply chain conformed to the same supply-side pattern. A logistics-industry analysis of COVID-19 vaccine distribution concluded that air-freight capacity and cold-chain infrastructure for ultra-cold vaccine storage were largely already in place or solvable with existing dry-ice production and new container technology, and that distribution costs made up only a small share of the total cost of a vaccine programme relative to the pandemic’s overall economic toll5. The risks it identified concerned coordination and information: the complexity of an unprecedented global vaccine rollout meant that not all operational details were known in advance, and the analysis called for developers, manufacturers, logistics providers and regulators to collaborate transparently rather than plan in isolation5. For a reviewer applying the three-driver framework of Ferdous et al., vaccines therefore provide a useful contrast case: the constraint concerned coordination across many independent actors more than physical production capacity, a different failure mode from the API or PPE shortages, even though all three fall within the same broad “pandemic medical supply chain disruption” literature.

Worked example: the surge in demand for medical oxygen

The “higher demand” driver of the framework is most evident in medical oxygen. The World Health Organization warned that COVID-19 patients in low- and middle-income countries needed more than 1.1 million oxygen cylinders a day at the peak of demand, with an estimated 15-20% of COVID-19 cases requiring supplemental oxygen and critically ill patients using as much as 30 litres per minute6. The WHO-led Oxygen Emergency Taskforce estimated $1.6 billion was needed over the following 12 months to close the gap in affected countries, and identified a structural problem behind the shortfall: many lower-income countries depend on oxygen cylinders and concentrators delivered by truck rather than on local, pipeline-based production, which makes their oxygen supply chains slower to scale and harder to maintain under sustained demand6. This was a demand-side shock that exposed a pre-existing structural weakness in production geography, rather than one that merely depleted existing inventory.

Shortages predating the pandemic

Not every pandemic-era drug shortage was caused by the pandemic. The University of Minnesota's Resilient Drug Supply Project found that 32 of the 40 drugs the FDA deemed essential for treating COVID-19 patients — including paralytics used for ventilator support and common medications such as acetaminophen — were already in short supply, and project lead Stephen Schondelmeyer noted that some of these drugs had been chronically scarce for more than two decades before COVID-197. Rising pandemic-era demand clearly worsened these shortages, but it did not create the underlying fragility; a review that attributes every drug shortage identified during this period to COVID-19 alone risks overlooking the pre-existing manufacturing concentration and low-margin economics of generic medicines, which the “reduced product supply” driver of Ferdous et al. should, in a fuller analysis, trace back to the period before 2020.

Controlled medicines and the shift towards online pharmacy

Two further strands of the literature elaborate the “shifts in consumer purchasing behaviour” driver. A briefing note from palliative care and drug-policy specialists warned that internationally controlled essential medicines (opioid analgesics and sedatives such as midazolam and diazepam, used for pain and respiratory distress) were already difficult to access for roughly 80% of the world’s population before the pandemic, and that COVID-19 demand, price rises, supply disruption and export restrictions were set to worsen stockouts that were already common in hospitals across the US, Europe and lower-income countries8. On the purchasing-behaviour side specifically, a survey of 2,087 consumers across the Visegrad Group countries found the share buying medicines online rose from 49.16% to 55.48% during the pandemic, and the share buying health products online rose from 60.61% to 63.0%, though the authors describe the longer-term shift in attitude as modest rather than transformative9. Both findings fall within Ferdous et al.’s third driver but point to two different mechanisms within it: scarcity-driven behaviour around controlled medicines, and a genuine, if limited, shift in purchasing channel toward e-pharmacy that outlasted the acute pandemic period.

Manufacturing concentration as the root cause underlying all three drivers

Several of the worked examples above trace back to the same underlying structural fact: pharmaceutical manufacturing, and especially active ingredient production, is heavily concentrated in a small number of countries. An industry coalition report found that around 83% of the top 100 prescribed generic medications in the United States depend on active pharmaceutical ingredients not manufactured domestically, and that roughly 90% of antiviral and antibiotic medications rely on APIs sourced from outside the country10. That concentration converted a single country’s export restriction, a single region’s production halt, or a single demand spike into a multi-country cascade of disruption; it is the structural precondition behind the API, PPE and oxygen case studies alike, and it is why Ferdous et al. recommended studying supply chain resilience at the regional level rather than assuming that disruption unfolds identically everywhere.

Key points

Key points

Pandemic-era disruption of the medical supply chain is most usefully analysed by separating the evidence into its three distinct drivers — supply-side production and border effects, demand-side surges and shifts in purchasing behaviour — rather than treating disruption as a single undifferentiated shock.

Practical application

Practical application

  1. A PRISMA-guided scoping method should be used for fast-growing literatures. Where a topic has accumulated rapidly across disciplines, a scoping review with documented screening stages maps the field more usefully than an early narrow systematic review.
  2. Code studies by disruption driver. When reviewing or extending this literature, each source should be classified by whether it addresses supply-side, demand-side or behavioural drivers of disruption, following the review’s own framework.
  3. Keep the analysis regionally specific. Because the framework was built to support regional analysis, findings should not be aggregated into a single global claim without verifying that the underlying studies were regionally comparable.

Frequently asked questions

A scoping review, as used by Ferdous et al., is designed to map the breadth and structure of a fast-growing literature using a transparent PRISMA-guided screening process, while a systematic review typically targets a narrower, pre-registered question with stricter quality-appraisal and synthesis requirements.

The review identified three: reduced product supply from production halts and border closures, increased demand for healthcare products, and shifts in consumer purchasing behaviour.

No. The University of Minnesota’s Resilient Drug Supply Project found that 32 of the 40 drugs the FDA deemed essential for COVID-19 care were already in short supply, and some had been chronically scarce for more than two decades before the pandemic, so rising demand worsened pre-existing fragility rather than creating it.

Pharmaceutical manufacturing is heavily concentrated: India alone supplies about a fifth of the world's generic medicines and roughly a quarter of US drug imports, while depending on China for most of its own active ingredients, so a single country's export restriction or production halt can cascade through two or three supply tiers before reaching a patient in another country.

References

  1. Ferdous J, Medhekar A, Akbar D, Khandaker G, Hossain MR. Developing an Analytical Framework to Depict Disruptions in the Pharmaceutical Supply Chain During COVID-19: A Scoping Review. Australasian Journal of Regional Studies. 2023;29(1):73-92. read 10 October 2026. View source
  2. Dienes BB, Qorri D, Felfoldi J. Pharma supply chain resilience: a systematic review. APSTRACT: Applied Studies in Agribusiness and Commerce. 2024;18(1). read 10 October 2026. View source
  3. Park C-Y, Kim K, Roth S, et al. Global Shortage of Personal Protective Equipment amid COVID-19: Supply Chains, Bottlenecks, and Policy Implications. ADB Briefs No. 130. Manila: Asian Development Bank; 2020. read 10 October 2026. View source
  4. Reed Smith LLP. India restricts drug exports over coronavirus fears. 2020. read 10 October 2026. View source
  5. Kuehne+Nagel. Shining a light on COVID-19 vaccine supply chains. read 10 October 2026. View source
  6. CIDRAP. WHO sounds alarm over COVID-linked oxygen crisis. Center for Infectious Disease Research and Policy, University of Minnesota. read 10 October 2026. View source
  7. Becker's ASC. 32 of 40 drugs deemed critical for COVID-19 in short supply. read 10 October 2026. View source
  8. Ahmed E, Cleary J, DeLima L, et al. Palliative Care in the COVID-19 Pandemic Briefing Note: Global Availability of Internationally Controlled Essential Medicines. IAHPC/Walther Center for Global Palliative Care; 2020. read 10 October 2026. View source
  9. Fittler A, Ambrus T, Serefko A, Smejkalova L, Kijewska A, Szopa A, Kaplar M. Attitudes and behaviors regarding online pharmacies in the aftermath of COVID-19 pandemic: at the tipping point towards the new normal. Frontiers in Pharmacology. 2022;13. read 10 October 2026. View source
  10. Active Pharmaceutical Ingredient Innovation Center. A Bold Goal: Reshoring 25% of Small Molecule API to the U.S. in Five Years. 2024, as reported by the Coalition for a Prosperous America. read 10 October 2026. View source

Every source above is a peer-reviewed article, a publisher’s record of one, or a standard issued by the body that owns it. Each carries the date it was last read. Where a standard moves, this article is revised rather than left up with a note.

How to cite this article

Pick your referencing style and copy it. Your university or target journal may vary the punctuation — check its guide if it has one.

Pubrica Academy. (2026, October 10). Mapping the Pandemic-Era Medical Supply Chain Literature: A Structured Review. Pubrica. https://pubrica.com/academy/concepts-definitions/a-structured-literature-review-and-bibliometric-network-analysis-of-pandemic-supply-chain-research/

This article is written to be learned from. Cite it if you are referring to what it says; if you are using the evidence behind it, cite the sources listed above instead.

Pandemic medical supply chain literature mapping checklist

This checklist is intended for use when structuring a review of pandemic-era pharmaceutical or medical supply chain research.

[ ] Screening method documented (PRISMA or equivalent flow)
[ ] Studies coded by disruption driver: supply-side, demand-side, behavioural
[ ] Regional scope of each study recorded, not assumed global
[ ] Framework or taxonomy from prior reviews cited and applied consistently
[ ] Gaps in regional or product-specific coverage identified for further research

Pubrica AcademyWritten and maintained by Pubrica’s subject matter experts. Articles are revised when the underlying standards change, and each article states the date on which it was last reviewed.

How Pubrica can help

Pubrica supports research teams conducting structured and bibliometric reviews of health system and medical supply chain literature, from search protocol design through to synthesis.

Find something else

Search the Pubrica Academy

Access is free and requires no account. Enter a topic, or open the full library to filter by category, sub-topic or resource type.

Structured mapping of the medical supply chain literature

A scoping assessment is free and takes two business days. It provides a written assessment of what the work requires and which specialist would undertake it.

Get a free quote

Regulations

Check your project against this rule

  1. 1Your work
  2. 2Your details
  3. 3Send
What do you need?

Material you send is held under signed confidentiality, with access limited to the assigned team and encrypted transfer. It is not used to train anything and is not passed to third-party tools. Ask for the agreement before you send anything you would rather cover first.